{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:57:12Z","timestamp":1793303832276,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"SuZhou Municipal Health Commission Project","award":["SKY2022165"],"award-info":[{"award-number":["SKY2022165"]}]},{"name":"Jiangsu Research Hospital Association for Precision Medication","award":["JY202217"],"award-info":[{"award-number":["JY202217"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cerebellum"],"DOI":"10.1007\/s12311-025-01873-4","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T18:19:53Z","timestamp":1750270793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Characteristics of Adverse Events and Clinical Risks of Omaveloxolone Based on FAERS Data"],"prefix":"10.1007","volume":"24","author":[{"given":"Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"1873_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ncl.2014.09.004","volume":"33","author":"U Akbar","year":"2015","unstructured":"Akbar U, Ashizawa T. Ataxia. Neurol Clin. 2015;33:225\u201348.","journal-title":"Neurol Clin"},{"key":"1873_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41582-025-01065-y","volume":"21","author":"E Indelicato","year":"2025","unstructured":"Indelicato E, Delatycki MB, Farmer J, Fran\u00e7a MC Jr, Perlman S, Rai M, et al. A global perspective on research advances and future challenges in Friedreich ataxia. Nat Rev Neurol. 2025;21:204\u201315.","journal-title":"Nat Rev Neurol"},{"key":"1873_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2217\/nmt-2022-0011","volume":"12","author":"M Keita","year":"2022","unstructured":"Keita M, McIntyre K, Rodden LN, Schadt K, Lynch DR. Friedreich ataxia: clinical features and new developments. Neurodegener Dis Manag. 2022;12:267\u201383.","journal-title":"Neurodegener Dis Manag"},{"key":"1873_CR4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1089\/ars.2006.8.438","volume":"8","author":"R Lodi","year":"2006","unstructured":"Lodi R, Tonon C, Calabrese V, Schapira AH. Friedreich\u2019s ataxia: from disease mechanisms to therapeutic interventions. Antioxid Redox Signal. 2006;8:438\u201343.","journal-title":"Antioxid Redox Signal"},{"key":"1873_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","volume":"303","author":"AH Koeppen","year":"2011","unstructured":"Koeppen AH. Friedreich\u2019s ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011;303:1\u201312.","journal-title":"J Neurol Sci"},{"key":"1873_CR6","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/acn3.52057","volume":"11","author":"C Rummey","year":"2024","unstructured":"Rummey C, Perlman S, Subramony SH, Farmer J, Lynch DR. Evaluating mFARS in pediatric Friedreich\u2019s ataxia: Insights from the FACHILD study. Ann Clin Transl Neurol. 2024;11:1290\u2013300.","journal-title":"Ann Clin Transl Neurol"},{"issue":"Suppl 1","key":"1873_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/jnc.12217","volume":"126","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, St\u00f6rk S, Liu D, Hu K, Herrmann S, Ertl G, et al. Cardiomyopathy of Friedreich ataxia. J Neurochem. 2013;126(Suppl 1):88\u201393.","journal-title":"J Neurochem"},{"key":"1873_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/archdischild-2021-322455","volume":"107","author":"G Norrish","year":"2022","unstructured":"Norrish G, Rance T, Montanes E, Field E, Brown E, Bhole V, et al. Friedreich\u2019s ataxia-associated childhood hypertrophic cardiomyopathy: a national cohort study. Arch Dis Child. 2022;107:450\u20135.","journal-title":"Arch Dis Child"},{"key":"1873_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13023-020-01475-9","volume":"15","author":"E Indelicato","year":"2020","unstructured":"Indelicato E, Nachbauer W, Eigentler A, Amprosi M, MatteucciGothe R, Giunti P, et al. Onset features and time to diagnosis in Friedreich\u2019s Ataxia. Orphanet J Rare Dis. 2020;15:198.","journal-title":"Orphanet J Rare Dis"},{"key":"1873_CR10","doi-asserted-by":"publisher","first-page":"109828","DOI":"10.1016\/j.diabres.2022.109828","volume":"186","author":"J Tamaroff","year":"2022","unstructured":"Tamaroff J, DeDio A, Wade K, Wells M, Park C, Leavens K, et al. Friedreich\u2019s Ataxia related Diabetes: Epidemiology and management practices. Diabetes Res Clin Pract. 2022;186:109828.","journal-title":"Diabetes Res Clin Pract"},{"key":"1873_CR11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40265-023-01874-9","volume":"83","author":"LA Omaveloxolone","year":"2023","unstructured":"Omaveloxolone LA. First Approval. Drugs. 2023;83:725\u20139.","journal-title":"Drugs"},{"key":"1873_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s13023-024-03474-6","volume":"19","author":"A Umrao","year":"2024","unstructured":"Umrao A, Pahuja M, Chatterjee NS. Safety and efficacy of omaveloxolone v\/s placebo for the treatment of Friedreich\u2019s ataxia in patients aged more than 16 years: a systematic review. Orphanet J Rare Dis. 2024;19:495.","journal-title":"Orphanet J Rare Dis"},{"key":"1873_CR13","first-page":"258","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard A. FDA approves first Friedreich\u2019s ataxia drug. Nat Rev Drug Discov. 2023;22:258.","journal-title":"Nat Rev Drug Discov"},{"key":"1873_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.molmed.2023.12.002","volume":"30","author":"F Pilotto","year":"2024","unstructured":"Pilotto F, Chellapandi DM, Puccio H. Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia. Trends Mol Med. 2024;30:117\u201325.","journal-title":"Trends Mol Med"},{"key":"1873_CR15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","volume":"89","author":"DR Lynch","year":"2021","unstructured":"Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC, et al. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). Ann Neurol. 2021;89:212\u201325.","journal-title":"Ann Neurol"},{"key":"1873_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s10194-024-01913-0","volume":"25","author":"WH Liu","year":"2024","unstructured":"Liu WH, Hu HM, Li C, Shi Q, Liu CH, Liu AX, et al. Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database. J Headache Pain. 2024;25:206.","journal-title":"J Headache Pain"},{"key":"1873_CR17","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","volume":"59","author":"C Zhou","year":"2023","unstructured":"Zhou C, Peng S, Lin A, Jiang A, Peng Y, Gu T, et al. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine. 2023;59:101967.","journal-title":"EClinicalMedicine"},{"key":"1873_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13195-024-01669-4","volume":"17","author":"X Xing","year":"2025","unstructured":"Xing X, Zhang X, Wang K, Wang Z, Feng Y, Li X, et al. Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database. Alzheimers Res Ther. 2025;17:15.","journal-title":"Alzheimers Res Ther"},{"key":"1873_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","volume":"347","author":"H Zhu","year":"2024","unstructured":"Zhu H, Qu Y, Du Z, Zhou Q, Shen Y, Jiang Y, et al. Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database. J Affect Disord. 2024;347:45\u201350.","journal-title":"J Affect Disord"},{"key":"1873_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00002018-200326030-00002","volume":"26","author":"EG Brown","year":"2003","unstructured":"Brown EG. Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf. 2003;26:145\u201358.","journal-title":"Drug Saf"},{"key":"1873_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement. Drug Saf. 2024;47:575\u201384.","journal-title":"Drug Saf"},{"key":"1873_CR22","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/pds.5624","volume":"32","author":"P Trillenberg","year":"2023","unstructured":"Trillenberg P, Sprenger A, Machner B. Sensitivity and specificity in signal detection with the reporting odds ratio and the information component. Pharmacoepidemiol Drug Saf. 2023;32:910\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1873_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1873_CR24","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00228-020-02909-w","volume":"76","author":"K Tada","year":"2020","unstructured":"Tada K, Maruo K, Isogawa N, Yamaguchi Y, Gosho M. Borrowing external information to improve Bayesian confidence propagation neural network. Eur J Clin Pharmacol. 2020;76:1311\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"1873_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93:539\u201346.","journal-title":"Clin Pharmacol Ther"},{"key":"1873_CR26","doi-asserted-by":"publisher","first-page":"e34837","DOI":"10.1016\/j.heliyon.2024.e34837","volume":"10","author":"J Zhu","year":"2024","unstructured":"Zhu J, Hu M, Liang Y, Zhong M, Chen Z, Wang Z, et al. Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database. Heliyon. 2024;10:e34837.","journal-title":"Heliyon"},{"key":"1873_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/14737175.2024.2310617","volume":"24","author":"DR Lynch","year":"2024","unstructured":"Lynch DR, Perlman S, Schadt K. Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations. Expert Rev Neurother. 2024;24:251\u20138.","journal-title":"Expert Rev Neurother"},{"key":"1873_CR28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00246-024-03429-5","volume":"46","author":"DR Lynch","year":"2024","unstructured":"Lynch DR, Subramony S, Lin KY, Mathews K, Perlman S, Yoon G, et al. Characterization of Cardiac-Onset Initial Presentation in Friedreich Ataxia. Pediatr Cardiol. 2024;46:379\u201382.","journal-title":"Pediatr Cardiol"},{"key":"1873_CR29","doi-asserted-by":"publisher","unstructured":"Jin X, Chen L, Yang Y, Tan R, Jiang C. Adverse effects of Nrf2 in different organs and the related diseases.\u00a0Antioxid Redox Signal. 2024. https:\/\/doi.org\/10.1089\/ars.2024.0586.","DOI":"10.1089\/ars.2024.0586"},{"key":"1873_CR30","doi-asserted-by":"crossref","unstructured":"Dobrek L. Lower urinary tract disorders as adverse drug reactions-a literature review. Pharmaceuticals (Basel). 2023;16:1031.","DOI":"10.3390\/ph16071031"},{"key":"1873_CR31","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.2337\/db22-0623","volume":"71","author":"M Dodson","year":"2022","unstructured":"Dodson M, Shakya A, Anandhan A, Chen J, Garcia JGN, Zhang DD. NRF2 and Diabetes: The Good, the Bad, and the Complex. Diabetes. 2022;71:2463\u201376.","journal-title":"Diabetes"},{"key":"1873_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/iju.13265","volume":"24","author":"T Feng","year":"2017","unstructured":"Feng T, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, et al. Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study. Int J Urol. 2017;24:151\u20136.","journal-title":"Int J Urol"},{"key":"1873_CR33","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.jiac.2021.05.012","volume":"27","author":"J Kamei","year":"2021","unstructured":"Kamei J, Yamamoto S. Complicated urinary tract infections with diabetes mellitus. J Infect Chemother. 2021;27:1131\u20136.","journal-title":"J Infect Chemother"},{"key":"1873_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ccl.2008.09.010","volume":"27","author":"NS Sawhney","year":"2009","unstructured":"Sawhney NS, Anousheh R, Chen WC, Feld GK. Diagnosis and management of typical atrial flutter. Cardiol Clin. 2009;27:55\u201367.","journal-title":"Cardiol Clin"},{"key":"1873_CR35","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1001\/jamacardio.2019.2724","volume":"4","author":"CP McCarthy","year":"2019","unstructured":"McCarthy CP, Raber I, Chapman AR, Sandoval Y, Apple FS, Mills NL, et al. Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin Assays: A Practical Approach for Clinicians. JAMA Cardiol. 2019;4:1034\u201342.","journal-title":"JAMA Cardiol"}],"container-title":["The Cerebellum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-025-01873-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12311-025-01873-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-025-01873-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T06:45:01Z","timestamp":1751611501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12311-025-01873-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["1873"],"URL":"https:\/\/doi.org\/10.1007\/s12311-025-01873-4","relation":{},"ISSN":["1473-4230"],"issn-type":[{"value":"1473-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"10 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"119"}}